Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 87

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 87
---
,017,344 |   |     | $           |  4,526,015 |   |     | $           |  6,034,687 |   |
| Total Uses                                                 |     | $                 | 10,041,724 |   |     | $           | 11,550,394 |   |     | $           | 13,059,074 |   |     | $           | 14,567,744 |   |     | $           | 16,076,414 |   |

____________ Notes:- (1)The amount left in trust was calculated as cash held in Trust Account as of June 30, 2024, plus accrued interest receivable adjusted for reductions in the Trust Account reflecting the various redemption scenarios (based on the estimated per -shareredemption price of approximately $11.60 per share as of June 30, 2024) and gives effect to redemptions of Public Shares made after the December 2024 EGM. (2)Cash and cash equivalents held by OmnigenicsAI as of June 30, 2024. (3)Assumes that Theo will satisfy its obligations under the Backstop Agreement pursuant to the subscription of up to 1,000,000 Company Shares at a subscription price of $10.00 per Company Share. See “ Certain Agreements Related to the Business Combination — Backstop Agreement.” (4)Calculated based on the estimated per -shareredemption price of approximately $11.60 per Public Share as of June 30, 2024. Certain United States Federal Income Tax Considerations For a discussion summarizing the material United States federal income tax considerations of an exercise of Redemption Rights, please see “ Material U.S. Federal Income Tax Considerations” below. Accounting Treatment of the Business Combination OmnigenicsAI will account for the Business Combination as a capital reorganization in accordance with IFRS as issued by the IASB. Under this method of accounting, APx will be treated as the “acquired” company for financial reporting purposes and OmngenicsAI will be the accounting “acquirer.” This determination was primarily based on the assumptions that OmngenicsAI’s shareholders will hold a majority of the voting power of the Combined Company, the Combined Company’s operations will substantially comprise the ongoing operations of OmngenicsAI, OmngenicsAI’s designees are expected to comprise a majority of the governing body of the Combined Company, and OmngenicsAI’s senior